deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01514526

Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Sponsor: Spanish Oncology Genito-Urinary Group

Conditions Adrenocortical Carcinoma
Interventions Dovitinib
Updated 6 times since 2017 Last updated: Apr 24, 2017 Started: Jan 31, 2012 Primary completion: Jul 31, 2013 Completion: Nov 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adrenocortical Carcinoma and is currently completed. Spanish Oncology Genito-Urinary Group leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshotActive Not Recruiting~May 2017 – ~Jun 2018 · 13 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 20 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. May 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

  1. Jan 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Spanish Oncology Genito-Urinary Group
Data source: Spanish Oncology Genito-Urinary Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations